Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
a minimum of at least 6
months for toenail infections.
DRUG INTERACTIONS: Griseofulvin interacts with many drugs. Patients should
consult the prescribing information for a complete list of drugs that interact
with griseofulvin. Known drug interactions include:
Griseofulvin increases the activity of CYP3A4
liver enzymes. Griseofulvin should not be combined with other drugs that are
metabolized (broken down) by CYP3A4 enzymes because griseofulvin may decrease
their blood concentrations, decreasing treatment effectiveness. Examples of
drugs metabolized by CYP3A4 enzymes include atazanavir (Reyataz), bedaquiline (Sirturo),
daclatasvir (Daklinza), darunavir (Prezista), gefitinib (Iressa), nilotinib (Tasigna),
palbociclib (Ibrance), telithromycin (Ketek), and several other drugs.
Use of griseofulvin with birth control pills
may reduce the effectiveness of birth control pills and cause breakthrough
bleeding. Patients should use an alternative or additional form of birth control
(contraception) while on griseofulvin therapy and for up to 1 month after
The effectiveness of warfarin (Coumadin,
Jantoven) may be reduced by griseofulvin because griseofulvin may increase the
breakdown warfarin by enzymes in the liver.